In particular, these drugs target the splenic MDSCs, which then facilitates the immune invasion, to enhance IFN-gamma production by tumor-specific CD8(+) T-cells infiltrating the tumor, promoting the T-cell-dependent anti-tumor responses. Here, CD8A is linked to neoplasm.